DalsnaFinance

Genespire and SR-TIGET Show Durable Preclinical Efficacy of Liver-Directed Gene Therapy for Methylmalonic Acidemia

Markets PR Newswire By PR Newswire 08 Jul 2026 07:00 1 min read
Genespire and SR-TIGET Show Durable Preclinical Efficacy of Liver-Directed Gene Therapy for Methylmalonic Acidemia

The study shows that ISLV-directed delivery of the MMUT gene produced durable therapeutic benefits in mouse models. Gene transfer efficiency exceeded 80% of the liver. Genespire is progressing its lead asset for MMA, GENE202, towards the clinic. MILAN, July 8, 2026 /PRNewswire/ --...

The study shows that ISLV-directed delivery of the MMUT gene produced durable therapeutic benefits in mouse models. Gene transfer efficiency exceeded 80% of the liver. Genespire is progressing its lead asset for MMA, GENE202, towards the clinic. MILAN, July 8, 2026 /PRNewswire/ --...

Read the full story on PR Newswire → Opens the original article on www.prnewswire.com

Summary aggregated from PR Newswire's public RSS feed. The full reporting belongs to PR Newswire — please read it on their site.